Is Revolution Medicines a Good Stock to Own?
Though it’s still quite early in the year, pharmaceutical startup…
Buy
61
TWST Quote, Financials, Valuation and Earnings
Last price:
$41.20
Seasonality move
:
-11.93%
Day range:
$38.65 - $40.90
52-week range:
$23.30 - $55.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.39x
P/B ratio:
5.19x
Volume:
1.2M
Avg. volume:
1.2M
1-year change:
-6.36%
Market cap:
$2.5B
Revenue:
$376.6M
EPS (TTM):
-$1.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TWST
Twist Bioscience Corp.
|
$100.4M | -$0.52 | 12.47% | -2.62% | $39.00 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -1.23% | -39.14% | $12.3077 |
|
ENOV
Enovis Corp.
|
$584.7M | $0.82 | 4.14% | 1731.46% | $45.45 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
LFWD
Lifeward Ltd.
|
$7.9M | -$0.09 | 4.27% | -94.81% | $7.25 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TWST
Twist Bioscience Corp.
|
$40.03 | $39.00 | $2.5B | -- | $0.00 | 0% | 6.39x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.6200 | $12.3077 | $194.8M | -- | $0.00 | 0% | 177.65x |
|
ENOV
Enovis Corp.
|
$24.27 | $45.45 | $1.4B | -- | $0.00 | 0% | 0.62x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.72 | $14.20 | $177.3M | 33.35x | $0.00 | 0% | 1.31x |
|
LFWD
Lifeward Ltd.
|
$0.66 | $7.25 | $11.6M | -- | $0.00 | 0% | 0.31x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.68 | $1.50 | $95.8M | 67.06x | $0.00 | 0% | 0.75x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TWST
Twist Bioscience Corp.
|
13.78% | 0.672 | 4.43% | 3.17x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
ENOV
Enovis Corp.
|
41.63% | 0.509 | 82.96% | 0.86x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
LFWD
Lifeward Ltd.
|
1.82% | -2.286 | 1.98% | 0.94x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TWST
Twist Bioscience Corp.
|
$50.8M | -$29.9M | -14.27% | -16.74% | -30.24% | -$24.2M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ENOV
Enovis Corp.
|
$286.7M | $9M | -33.65% | -52.07% | 1.65% | $29.1M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
LFWD
Lifeward Ltd.
|
$2.7M | -$3.1M | -146.07% | -150.63% | -50.69% | -$3.8M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Twist Bioscience Corp. vs. Competitors
-
Which has Higher Returns TWST or CATX?
Perspective Therapeutics, Inc. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of -12425.36%. Twist Bioscience Corp.'s return on equity of -16.74% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital TWSTTwist Bioscience Corp.51.35% -$0.45 $548.5M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About TWST or CATX?
Twist Bioscience Corp. has a consensus price target of $39.00, signalling downside risk potential of -2.57%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 369.76%. Given that Perspective Therapeutics, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Perspective Therapeutics, Inc. is more attractive than Twist Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings TWSTTwist Bioscience Corp.7 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is TWST or CATX More Risky?
Twist Bioscience Corp. has a beta of 2.191, which suggesting that the stock is 119.099% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock TWST or CATX?
Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TWST or CATX?
Twist Bioscience Corp. quarterly revenues are $99M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Twist Bioscience Corp.'s net income of -$27.1M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 6.39x versus 177.65x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TWSTTwist Bioscience Corp.6.39x -- $99M -$27.1M CATXPerspective Therapeutics, Inc.177.65x -- $209K -$26M
-
Which has Higher Returns TWST or ENOV?
Enovis Corp. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of -104%. Twist Bioscience Corp.'s return on equity of -16.74% beat Enovis Corp.'s return on equity of -52.07%.
Company Gross Margin Earnings Per Share Invested Capital TWSTTwist Bioscience Corp.51.35% -$0.45 $548.5M ENOVEnovis Corp.52.24% -$9.99 $3.5B -
What do Analysts Say About TWST or ENOV?
Twist Bioscience Corp. has a consensus price target of $39.00, signalling downside risk potential of -2.57%. On the other hand Enovis Corp. has an analysts' consensus of $45.45 which suggests that it could grow by 87.29%. Given that Enovis Corp. has higher upside potential than Twist Bioscience Corp., analysts believe Enovis Corp. is more attractive than Twist Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings TWSTTwist Bioscience Corp.7 2 0 ENOVEnovis Corp.9 1 0 -
Is TWST or ENOV More Risky?
Twist Bioscience Corp. has a beta of 2.191, which suggesting that the stock is 119.099% more volatile than S&P 500. In comparison Enovis Corp. has a beta of 1.286, suggesting its more volatile than the S&P 500 by 28.564%.
-
Which is a Better Dividend Stock TWST or ENOV?
Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. Enovis Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TWST or ENOV?
Twist Bioscience Corp. quarterly revenues are $99M, which are smaller than Enovis Corp. quarterly revenues of $548.9M. Twist Bioscience Corp.'s net income of -$27.1M is higher than Enovis Corp.'s net income of -$570.9M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while Enovis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 6.39x versus 0.62x for Enovis Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TWSTTwist Bioscience Corp.6.39x -- $99M -$27.1M ENOVEnovis Corp.0.62x -- $548.9M -$570.9M
-
Which has Higher Returns TWST or INFU?
InfuSystem Holdings, Inc. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of 6.19%. Twist Bioscience Corp.'s return on equity of -16.74% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital TWSTTwist Bioscience Corp.51.35% -$0.45 $548.5M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About TWST or INFU?
Twist Bioscience Corp. has a consensus price target of $39.00, signalling downside risk potential of -2.57%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 62.84%. Given that InfuSystem Holdings, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe InfuSystem Holdings, Inc. is more attractive than Twist Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings TWSTTwist Bioscience Corp.7 2 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is TWST or INFU More Risky?
Twist Bioscience Corp. has a beta of 2.191, which suggesting that the stock is 119.099% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock TWST or INFU?
Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TWST or INFU?
Twist Bioscience Corp. quarterly revenues are $99M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Twist Bioscience Corp.'s net income of -$27.1M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 6.39x versus 1.31x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TWSTTwist Bioscience Corp.6.39x -- $99M -$27.1M INFUInfuSystem Holdings, Inc.1.31x 33.35x $36.5M $2.3M
-
Which has Higher Returns TWST or LFWD?
Lifeward Ltd. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of -51.17%. Twist Bioscience Corp.'s return on equity of -16.74% beat Lifeward Ltd.'s return on equity of -150.63%.
Company Gross Margin Earnings Per Share Invested Capital TWSTTwist Bioscience Corp.51.35% -$0.45 $548.5M LFWDLifeward Ltd.43.7% -$0.20 $13M -
What do Analysts Say About TWST or LFWD?
Twist Bioscience Corp. has a consensus price target of $39.00, signalling downside risk potential of -2.57%. On the other hand Lifeward Ltd. has an analysts' consensus of $7.25 which suggests that it could grow by 1006.2%. Given that Lifeward Ltd. has higher upside potential than Twist Bioscience Corp., analysts believe Lifeward Ltd. is more attractive than Twist Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings TWSTTwist Bioscience Corp.7 2 0 LFWDLifeward Ltd.1 0 0 -
Is TWST or LFWD More Risky?
Twist Bioscience Corp. has a beta of 2.191, which suggesting that the stock is 119.099% more volatile than S&P 500. In comparison Lifeward Ltd. has a beta of 0.002, suggesting its less volatile than the S&P 500 by 99.817%.
-
Which is a Better Dividend Stock TWST or LFWD?
Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. Lifeward Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TWST or LFWD?
Twist Bioscience Corp. quarterly revenues are $99M, which are larger than Lifeward Ltd. quarterly revenues of $6.2M. Twist Bioscience Corp.'s net income of -$27.1M is lower than Lifeward Ltd.'s net income of -$3.2M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while Lifeward Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 6.39x versus 0.31x for Lifeward Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TWSTTwist Bioscience Corp.6.39x -- $99M -$27.1M LFWDLifeward Ltd.0.31x -- $6.2M -$3.2M
-
Which has Higher Returns TWST or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -27.41% compared to Twist Bioscience Corp.'s net margin of 3.93%. Twist Bioscience Corp.'s return on equity of -16.74% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital TWSTTwist Bioscience Corp.51.35% -$0.45 $548.5M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About TWST or XTNT?
Twist Bioscience Corp. has a consensus price target of $39.00, signalling downside risk potential of -2.57%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.3%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Xtant Medical Holdings, Inc. is more attractive than Twist Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings TWSTTwist Bioscience Corp.7 2 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is TWST or XTNT More Risky?
Twist Bioscience Corp. has a beta of 2.191, which suggesting that the stock is 119.099% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock TWST or XTNT?
Twist Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Twist Bioscience Corp. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TWST or XTNT?
Twist Bioscience Corp. quarterly revenues are $99M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Twist Bioscience Corp.'s net income of -$27.1M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Twist Bioscience Corp.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 67.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Twist Bioscience Corp. is 6.39x versus 0.75x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TWSTTwist Bioscience Corp.6.39x -- $99M -$27.1M XTNTXtant Medical Holdings, Inc.0.75x 67.06x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Has Vistra Stock Gone Up?
Integrated power generation business Vistra (NYSE:VST) surprised investors recently when…
Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
53
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
80
BNR alert for Jan 15
Burning Rock Biotech Ltd. [BNR] is up 19.14% over the past day.
Sell
37
TCOM alert for Jan 15
Trip.com Group Ltd. [TCOM] is down 2.56% over the past day.
Sell
39
DAVE alert for Jan 15
Dave, Inc. [DAVE] is up 2.88% over the past day.
